Cabotegravir and Rilpivirine
Brand Names: Cabenuva
Methodology & AI Transparency ⓘ
Cabotegravir and Rilpivirine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage cabenuva: is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine .
- 2 Real-world patient consensus: Zero-PHI community consensus: 79% favorable across 15 logged regimens (Cabenuva).
- 3 Typical cash cost range: 30-day cash pricing ranges from $61.56 discount cash to $150.82 walk-in retail (NADAC $1.3100/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Cabotegravir and Rilpivirine): nausea (13.1%), headache (11.7%), dizziness (7.4%).
Ask our AI Specialists anything about Cabotegravir and Rilpivirine
Cabotegravir and Rilpivirine Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage cabenuva: is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine .
12.1 Mechanism of Action CABENUVA contains 2 long-acting HIV-1 antiretroviral drugs, cabotegravir and rilpivirine . As an active fda prescription therapeutic agent moiety (ViiV Healthcare Company), Cabotegravir and Rilpivirine modulates physiological signaling proportional to Kit exposure and hepatorenal clearance (SPL 2025-11-26).
Following administration (Kit), Cabotegravir and Rilpivirine achieves Consistent 78%–90% gastrointestinal absorption profile for Cabotegravir and Rilpivirine bioavailability and cmax attained 2–3 hours post-administration of cabotegravir and rilpivirine onset, governed by a Elimination kinetics span 8 to 20 hours per Cabotegravir and Rilpivirine clinical pharmacology terminal half-life through systemic clearance of cabotegravir and rilpivirine integrates hepatic phase ii conjugation with renal filtration.
Before initiating Cabotegravir and Rilpivirine at Kit, clinical safety checklists rule out 4 contraindications cabenuva is contraindicated in patients:; with previous hypersensitivity reaction to cabotegravir or rilpivirine .. Logged tolerability patterns center on nausea (13.1% of reports), headache (11.7% of reports), dizziness (7.4% of reports).
Reconcile eGFR-adjusted medications before escalating Cabotegravir and Rilpivirine in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Cabotegravir and Rilpivirine dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS CABENUVA is contraindicated in patients:
- with previous hypersensitivity reaction to cabotegravir or rilpivirine .
Logged Side-Effect Incidence (15 Reports)
Cabotegravir and Rilpivirine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cabotegravir and Rilpivirine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation: What a 373-Participant Study Found CAB + RPV LA Q2M was well tolerated and highly effective in maintaining virologic suppression with a low rate of virologic failure. Journal of acquired immune deficiency syndromes (1999) • 2024-08-15 • Phase III Randomized Trial | N = 373 | 87/100 | PMID 38985445 ↗ |
| New Insights on Long-acting cabotegravir how the body absorbs the medicine with and without oral: What a 278-Participant Study Found Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. Antimicrobial agents and chemotherapy • 2024-06-05 • Phase III Randomized Trial | N = 278 | 87/100 | PMID 38709006 ↗ |
| Can This Approach Help? Inside the Latest Research on Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of In cabotegravir breakthrough experiments, time to breakthrough was similar between L74 and I74 viruses across HIV-1 subtypes B and A6; Q148R was selected at low cabotegravir concentrations. Antimicrobial agents and chemotherapy • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34978890 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, Safety, and how the body absorbs the medicine by Body Mass Index CAB + RPV LA was efficacious and well tolerated, regardless of baseline BMI category. The Journal of infectious diseases • 2024-07-25 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39052748 ↗ |
Cabotegravir and Rilpivirine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3100/unit (~$39.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $150.82 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $61.56 / mo | View logs ↓ |
Cabotegravir and Rilpivirine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cabotegravir and Rilpivirine RxNorm Concept ID | 2475415 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $150.82 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $61.56 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 79.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cabotegravir and Rilpivirine Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Cabotegravir and Rilpivirine: FDA labeling (2025-11-26, NDC 49702-240), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cabotegravir and Rilpivirine community threads and patient logs by age, biological sex, dosage, and treatment duration.